


PHARMACEUTICAL 2022



ALPINE IMMUNE SCIENCES INC. Rank 176 of 475





PHARMACEUTICAL 2022



ALPINE IMMUNE SCIENCES INC. Rank 176 of 475

The relative strengths and weaknesses of ALPINE IMMUNE SCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALPINE IMMUNE SCIENCES INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 55% points. The greatest weakness of ALPINE IMMUNE SCIENCES INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is -37%, being 240% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	192,013
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	69,778
Liabilities, Non-Current	65,219
Other Assets	62,171
Other Compr. Net Income	-326
Other Expenses	729
Other Liabilities	0
Other Net Income	255
Property and Equipment	1,716
Research and Development	58,742
Revenues	23,443
Selling, General and Administrative Expense	14,560

Output Variable	Value in 1000 USD
Assets	255,900
Liabilities	134,997
Expenses	74,031
Stockholders Equity	120,903
Net Income	-50,333
Comprehensive Net Income	-50,496
Economic Capital Ratio	-37%